ATE122041T1 - Pyrimidinnucleosidderivat. - Google Patents
Pyrimidinnucleosidderivat.Info
- Publication number
- ATE122041T1 ATE122041T1 AT91911192T AT91911192T ATE122041T1 AT E122041 T1 ATE122041 T1 AT E122041T1 AT 91911192 T AT91911192 T AT 91911192T AT 91911192 T AT91911192 T AT 91911192T AT E122041 T1 ATE122041 T1 AT E122041T1
- Authority
- AT
- Austria
- Prior art keywords
- pyrimidine nucleoside
- nucleoside derivative
- hydroxy
- hydrogen
- represent
- Prior art date
Links
- 150000003833 nucleoside derivatives Chemical class 0.000 title abstract 2
- 239000002718 pyrimidine nucleoside Substances 0.000 title abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15668890 | 1990-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE122041T1 true ATE122041T1 (de) | 1995-05-15 |
Family
ID=15633157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91911192T ATE122041T1 (de) | 1990-06-15 | 1991-06-13 | Pyrimidinnucleosidderivat. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5616567A (de) |
| EP (1) | EP0535231B1 (de) |
| JP (1) | JP2559917B2 (de) |
| KR (1) | KR970011306B1 (de) |
| AT (1) | ATE122041T1 (de) |
| CA (1) | CA2085345C (de) |
| DE (1) | DE69109482T2 (de) |
| DK (1) | DK0535231T3 (de) |
| ES (1) | ES2074719T3 (de) |
| HK (1) | HK1005871A1 (de) |
| HU (1) | HU218924B (de) |
| RU (1) | RU2116306C1 (de) |
| WO (1) | WO1991019713A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI105556B (fi) * | 1991-09-30 | 2000-09-15 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten pyrimidiiniukleosidijohdannaisten valmistamiseksi, joilla on kasvaimen vastaista vaikutusta |
| JP3265548B2 (ja) | 1992-05-12 | 2002-03-11 | メレルファーマス−ティカルズ インコーポレイテッド | リボヌクレオチド還元酵素阻害剤の製法 |
| EP1736478B1 (de) * | 2000-05-26 | 2015-07-22 | IDENIX Pharmaceuticals, Inc. | Verfahren und Zusammensetzungen zur Behandlung von Flaviviren und Pestiviren |
| JP3748536B2 (ja) * | 2001-02-09 | 2006-02-22 | 三共株式会社 | ピリミジンヌクレオシド誘導体の結晶 |
| TW200637870A (en) | 2005-01-31 | 2006-11-01 | Taiho Pharmaceutical Co Ltd | Novel pyrimidine nucleoside compound and salt thereof |
| DE602006016103D1 (de) * | 2005-05-11 | 2010-09-23 | Nippon Kayaku Kk | Polymer-derivat von cytidin metabolit antagonist |
| GB0523041D0 (en) * | 2005-11-11 | 2005-12-21 | Cyclacel Ltd | Combination |
| GB0526419D0 (en) * | 2005-12-23 | 2006-02-08 | Cyclacel Ltd | Formulation |
| EP2045256A4 (de) * | 2006-07-21 | 2009-09-02 | Taiho Pharmaceutical Co Ltd | 2'-cyanopyrimidinnukleosidverbindung |
| KR101057239B1 (ko) * | 2006-10-10 | 2011-08-16 | 에프. 호프만-라 로슈 아게 | 뉴클레오사이드 리보푸라노실 피리미딘의 제조 |
| GB0625283D0 (en) | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| WO2009042767A1 (en) * | 2007-09-26 | 2009-04-02 | Mount Sinai School Of Medicine | Azacytidine analogues and uses thereof |
| US8124593B2 (en) | 2007-11-05 | 2012-02-28 | Cyclacel Limited | Methods of treatment using sapacitabine |
| US7863255B2 (en) * | 2008-04-29 | 2011-01-04 | Taiho Pharmaceutical Co., Ltd. | Methods of administering antitumor agent comprising deoxycytidine derivative |
| GB0808357D0 (en) * | 2008-05-08 | 2008-06-18 | Cyclacel Ltd | Process |
| GB0808359D0 (en) * | 2008-05-08 | 2008-06-18 | Cyclacel Ltd | Process |
| AU2009259136B2 (en) | 2008-06-09 | 2014-09-25 | Cyclacel Limited | Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine |
| FI2431376T4 (fi) * | 2009-05-15 | 2024-03-13 | Delta Fly Pharma Inc | 1-(2'-syano-2'-deoksi-beeta-D-arabinofuranosyyli)sytosiinimonohydrokloridin uusi vakaa kide |
| PL2696878T3 (pl) | 2011-04-14 | 2020-01-31 | Cyclacel Limited | Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej |
| SG10201913554YA (en) | 2011-12-22 | 2020-03-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| JP6286421B2 (ja) | 2012-05-15 | 2018-02-28 | サイクラセル リミテッド | サパシタビン及びセリシクリブの投与レジメン |
| WO2019081951A1 (en) | 2017-10-27 | 2019-05-02 | Cyclacel Limited | DOSAGE REGIME |
| EP4183397A4 (de) | 2020-07-17 | 2024-03-27 | Delta-Fly Pharma, Inc. | Neue therapie und neues therapeutikum für blutkrebs |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2007094A6 (es) * | 1987-07-29 | 1989-06-01 | Consejo Superior Investigacion | Procedimiento para la preparacion de 3 -c- ciano-2,3 -didesoxinucleosido. |
-
1991
- 1991-06-11 JP JP3138859A patent/JP2559917B2/ja not_active Expired - Lifetime
- 1991-06-13 CA CA002085345A patent/CA2085345C/en not_active Expired - Lifetime
- 1991-06-13 HU HU9203967A patent/HU218924B/hu unknown
- 1991-06-13 AT AT91911192T patent/ATE122041T1/de not_active IP Right Cessation
- 1991-06-13 KR KR1019920703246A patent/KR970011306B1/ko not_active Expired - Lifetime
- 1991-06-13 EP EP91911192A patent/EP0535231B1/de not_active Expired - Lifetime
- 1991-06-13 ES ES91911192T patent/ES2074719T3/es not_active Expired - Lifetime
- 1991-06-13 DE DE69109482T patent/DE69109482T2/de not_active Expired - Lifetime
- 1991-06-13 WO PCT/JP1991/000797 patent/WO1991019713A1/ja not_active Ceased
- 1991-06-13 DK DK91911192.2T patent/DK0535231T3/da active
- 1991-06-13 RU RU92016591/04A patent/RU2116306C1/ru active
-
1994
- 1994-09-07 US US08/301,720 patent/US5616567A/en not_active Expired - Lifetime
-
1995
- 1995-06-01 US US08/457,510 patent/US5654420A/en not_active Expired - Lifetime
-
1998
- 1998-06-05 HK HK98104955A patent/HK1005871A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2116306C1 (ru) | 1998-07-27 |
| ES2074719T3 (es) | 1995-09-16 |
| EP0535231A1 (de) | 1993-04-07 |
| HU218924B (hu) | 2000-12-28 |
| HUT62582A (en) | 1993-05-28 |
| EP0535231A4 (en) | 1993-06-30 |
| EP0535231B1 (de) | 1995-05-03 |
| KR970011306B1 (ko) | 1997-07-09 |
| KR930700485A (ko) | 1993-03-15 |
| HK1005871A1 (en) | 1999-01-29 |
| DE69109482T2 (de) | 1996-02-15 |
| CA2085345C (en) | 2001-08-07 |
| DE69109482D1 (en) | 1995-06-08 |
| US5616567A (en) | 1997-04-01 |
| JP2559917B2 (ja) | 1996-12-04 |
| JPH04235182A (ja) | 1992-08-24 |
| HU9203967D0 (en) | 1993-03-29 |
| CA2085345A1 (en) | 1991-12-16 |
| US5654420A (en) | 1997-08-05 |
| WO1991019713A1 (fr) | 1991-12-26 |
| DK0535231T3 (da) | 1995-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE122041T1 (de) | Pyrimidinnucleosidderivat. | |
| ATE416186T1 (de) | Phenylethylenamin-derivate | |
| DE3851179D1 (de) | Oxetanocin. | |
| FI952101A0 (fi) | Merkaptanfoerening | |
| DK0784055T3 (da) | Pyrimidinylpyrazolderivater | |
| ATE86866T1 (de) | Antikrebs-zusammensetzung. | |
| FI940011A0 (fi) | Mono- ja bis-alkyyliaminoantrasykliinit | |
| ES2169220T3 (es) | Derivados de vitamina d3 con sustituyentes en la posicion 2. | |
| DK0424899T3 (da) | Hidtil ukendte anthracyclinglycosidderivater og fremgangsmåde til fremstilling deraf | |
| NO904187D0 (no) | Benzanilider. | |
| DK0601191T3 (da) | Hidtil ukendt tetracyklisk forbindelse | |
| ATE90685T1 (de) | Disaccharidderivate. | |
| BG60066B2 (bg) | Метод за получаване на 4-/3-/4-оксотиазолидин//бутиниламин | |
| DE69303847D1 (de) | Indolderivate | |
| ATE176242T1 (de) | Uck14-verbindungen | |
| GB0217638D0 (en) | Total synthesis of myriaporones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EEIH | Change in the person of patent owner | ||
| EEIH | Change in the person of patent owner | ||
| EELA | Cancelled due to lapse of time |